利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.086 秒)

    Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signal
    26.
    发明授权
    Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signal 有权
    识别在PD-1介导的信号存在下上调T细胞活化的化合物的方法

    公开(公告)号：US07432059B2

    公开(公告)日：2008-10-07

    申请号：US09895837

    申请日：2001-06-28

    申请人： Gordon Freeman ,  Irene Chernova ,  Tatyana Chernova ,  Nelly Malenkovich ,  Clive Wood ,  Yvette Latchman ,  Arlene H. Sharpe

    发明人： Gordon Freeman ,  Irene Chernova ,  Tatyana Chernova ,  Nelly Malenkovich ,  Clive Wood ,  Yvette Latchman ,  Arlene H. Sharpe

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6854 ,  G01N33/5014 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/573 ,  G01N2800/52

    摘要： The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. The invention further provides methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1-mediated signal. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供分离的核酸分子，命名为PD-L2核酸分子，其编码作为PD-1配体的新型B7相关分子。 本发明还提供了反义核酸分子，含有PD-L2核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及已导入或破坏了PD-L2基因的非人类转基因动物。 本发明进一步提供分离的PD-L2多肽，融合蛋白，抗原肽和抗-PD-L2抗体。 本发明还提供了促进或抑制PD-L2与PD-1之间相互作用的方法。 本发明还提供鉴定在PD-1介导的信号存在下上调T细胞活化的化合物的方法。 还提供了利用本发明组合物的诊断和治疗方法。

    Inhibition of T cell activation by butyrophilin 4 or B7-L1
    28.
    发明申请
    Inhibition of T cell activation by butyrophilin 4 or B7-L1 审中-公开
    抑制丁酸生物素4或B7-L1对T细胞的活化

    公开(公告)号：US20060233819A1

    公开(公告)日：2006-10-19

    申请号：US11477982

    申请日：2006-06-29

    申请人： Clive Wood ,  Andrew Long ,  Beatriz Carreno

    发明人： Clive Wood ,  Andrew Long ,  Beatriz Carreno

    IPC分类号： A61K39/00

    CPC分类号： C07K14/70532 ,  A61K38/00 ,  C07K14/70503 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/505

    摘要： The invention provides methods for modulating an immune response comprising contacting an immune cell with an agent that modulates BTF4 or B7-L1 mediated signaling. BTF4 or B7-L1 mediated signaling may either be increased, to thereby downregulate the immune response, or alternatively may be decreased, to upregulate the immune response. Modulation may be either activation or inhibition, and contacting may occur in vivo or in vitro. Performance of this method in vivo is also potentially therapeutic for an individual who may benefit from the upregulation or downregulation of an immune response. Such modulation to downregulate the immune response serves as a therapeutic e.g., for an individual who has received an organ transplant, or has a condition such as an allergy, or an autoimmune disorder. Alternatively, modulation to upregulate the immune response serves as a therapeutic for an individual, e.g., who has a condition such as an immunosuppressive disorder or a tumor. Methods for identifying an agent that modulates BTF4 signaling or B7-L1 signaling is also provided.

    摘要翻译： 本发明提供了调节免疫应答的方法，包括使免疫细胞与调节BTF4或B7-L1介导的信号传导的药剂接触。 可以增加BTF4或B7-L1介导的信号传导，从而下调免疫应答，或者可以减少上调免疫应答。 调节可以是活化或抑制，并且接触可以在体内或体外发生。 该方法在体内的表现对于可能受益于免疫反应的上调或下调的个体也是潜在的治疗剂。 用于下调免疫应答的这种调节用作治疗剂，例如对于已经接受器官移植或具有诸如过敏或自身免疫病症的病症的个体。 或者，用于上调免疫应答的调节用作个体的治疗剂，例如患有诸如免疫抑制障碍或肿瘤的病症的个体。 还提供了用于识别调节BTF4信令或B7-L1信令的试剂的方法。